New data put more non-inferior SPRING in dolutegravir's step
06:44 EDT 30 Jul 2012 | SCRIP
The Shionogi-ViiV Healthcare HIV drug joint venture has released additional findings from the SPRING-2 Phase III study with dolutegravir that further strengthen the case for the HIV integrase inhibitor's non-inferiority to Merck & Co's.....
Original Article: New data put more non-inferior SPRING in dolutegravir's step
More From BioPortfolio on "New data put more non-inferior SPRING in dolutegravir's step"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
